# A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

> **NCT07405151** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (estimated)

## Conditions studied

- Oesophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** I-DXd
- **DRUG:** Rescue Medication

## Key facts

- **NCT ID:** NCT07405151
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-06-12
- **Final completion:** 2028-06-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07405151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07405151, "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07405151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*